Daridorexant hydrochloride is under clinical development by Idorsia Pharmaceutical and currently in Phase II for Post-Traumatic Stress Disorder (PTSD). According to GlobalData, Phase II drugs for Post-Traumatic Stress Disorder (PTSD) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Daridorexant hydrochloride LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Daridorexant hydrochloride overview
Daridorexant Hydrochloride (Quviviq) is under development for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance and post-traumatic stress disorder (PTSD). The drug candidate is a sleep-inducing agent that is administered through oral route in the form of film coated tablets.
Daridorexant Hydrochloride is under development for the treatment of insomnia in adults and pediatrics and post-traumatic stress disorder. It is administered through oral route in the form of tablet. The drug candidate acts by targeting orexin receptor type 1 and type 2.
The drug candidate was under development for the treatment of obstructive sleep apnea.
Idorsia Pharmaceutical overview
Idorsia Pharmaceutical (Idorsia), a subsidiary of Idorsia Ltd, is a biopharmaceutical company. It discovers, develops, and commercializes therapies to treat central nervous system (CNS), cardiovascular, immunological disorders, and orphan diseases. The company’s product portfolio includes Quviviq, a daridorexant, to treat insomnia; Pivlaz, a clazosentan, for the treatment of cerebral vasospasm; and Tryvio, an aprocitentan, for the treatment of uncontrolled hypertension. Idorsia’s pipeline includes various drugs for the treatment of fabry disease, pediatric insomnia, demyelinating diseases, rare lysosomal storage disorders, recent-onset type 1diabetes, immune-mediated disorders, and clostridium difficile infection. The company has a vaccine platform for the development of glycoconjugate vaccines containing synthetic antigenic glycan molecules to prevent infection. It has a presence in Japan, the UK, South Korea, Switzerland, and the US. Idorsia is headquartered in Arlesheim, Basel-Landschaft, Switzerland.
For a complete picture of Daridorexant hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
